-
Vaccine Jun 1991The kinetics of inactivation of the infectivity of the influenza virus by beta-propiolactone have been studied. Rate constants have been determined for inactivation of...
The kinetics of inactivation of the infectivity of the influenza virus by beta-propiolactone have been studied. Rate constants have been determined for inactivation of the A/Leningrad/385 (H3N2) and B/Leningrad/489/80 influenza virus under the action of beta-propiolactone on a virus-containing allantoic fluid and on a purified viral suspension. The data obtained allow calculation of the time required for inactivation of the influenza virus infectivity to a given extent in virus-containing solutions at any initial concentration of beta-propiolactone.
Topics: Animals; Chick Embryo; Genes, Viral; Influenza A virus; Influenza B virus; Influenza Vaccines; Kinetics; Orthomyxoviridae; Propiolactone; Vaccines, Inactivated
PubMed: 1887669
DOI: 10.1016/0264-410x(91)90125-p -
Canadian Journal of Microbiology Oct 1957
Topics: Humans; Influenza Vaccines; Influenza, Human; Propiolactone; Propionates; Vaccines
PubMed: 13472512
DOI: 10.1139/m57-096 -
Biomacromolecules 2001Synthesis of an alpha,beta-alkyl branched polyester, i.e., poly(2-methyl-3-hydroxyoctanoate), has been accomplished via anionic polymerization of...
Synthesis of an alpha,beta-alkyl branched polyester, i.e., poly(2-methyl-3-hydroxyoctanoate), has been accomplished via anionic polymerization of alpha-methyl-beta-pentyl-beta-propiolactone mediated by supramolecular complexes of potassium methoxide or potassium hydroxide, respectively. The structure of resulting polymers has been established by electrospray ionization multistage mass spectrometry (ESI-MSn), FT-IR, NMR, and GPC analyses. Previously proposed addition-elimination mechanism of the polymerization of beta-lactones containing alpha-hydrogen by alkoxide anion has been confirmed to operate also in the case of beta-lactone having alkyl substituents in both alpha and beta positions.
Topics: Methods; Molecular Structure; Polyesters; Propiolactone; Spectrometry, Mass, Electrospray Ionization
PubMed: 11710013
DOI: 10.1021/bm015528q -
Viral Immunology Oct 2010The immunogenicity and efficacy of β-propiolactone (BPL) inactivated whole virion SARS-CoV (WI-SARS) vaccine was evaluated in BALB/c mice and golden Syrian hamsters....
The immunogenicity and efficacy of β-propiolactone (BPL) inactivated whole virion SARS-CoV (WI-SARS) vaccine was evaluated in BALB/c mice and golden Syrian hamsters. The vaccine preparation was tested with or without adjuvants. Adjuvant Systems AS01(B) and AS03(A) were selected and tested for their capacity to elicit high humoral and cellular immune responses to WI-SARS vaccine. We evaluated the effect of vaccine dose and each adjuvant on immunogenicity and efficacy in mice, and the effect of vaccine dose with or without the AS01(B) adjuvant on the immunogenicity and efficacy in hamsters. Efficacy was evaluated by challenge with wild-type virus at early and late time points (4 and 18 wk post-vaccination). A single dose of vaccine with or without adjuvant was poorly immunogenic in mice; a second dose resulted in a significant boost in antibody levels, even in the absence of adjuvant. The use of adjuvants resulted in higher antibody titers, with the AS01(B)-adjuvanted vaccine being slightly more immunogenic than the AS03(A)-adjuvanted vaccine. Two doses of WI-SARS with and without Adjuvant Systems were highly efficacious in mice. In hamsters, two doses of WI-SARS with and without AS01(B) were immunogenic, and two doses of 2 μg of WI-SARS with and without the adjuvant provided complete protection from early challenge. Although antibody titers had declined in all groups of vaccinated hamsters 18 wk after the second dose, the vaccinated hamsters were still partially protected from wild-type virus challenge. Vaccine with adjuvant provided better protection than non-adjuvanted WI-SARS vaccine at this later time point. Enhanced disease was not observed in the lungs or liver of hamsters following SARS-CoV challenge, regardless of the level of serum neutralizing antibodies.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Neutralizing; Antibodies, Viral; Cricetinae; Disinfectants; Female; Immunization, Secondary; Liver; Lung; Mesocricetus; Mice; Mice, Inbred BALB C; Propiolactone; Severe acute respiratory syndrome-related coronavirus; Severe Acute Respiratory Syndrome; Survival Analysis; Vaccination; Vaccines, Inactivated; Viral Vaccines; Virus Inactivation
PubMed: 20883165
DOI: 10.1089/vim.2010.0028 -
Applied Microbiology Jul 1959
Topics: Animals; Anti-Infective Agents, Local; Encephalitis Virus, Venezuelan Equine; Encephalomyelitis; Encephalomyelitis, Equine; Encephalomyelitis, Venezuelan Equine; Gases; Horses; Propiolactone; Viruses
PubMed: 13661862
DOI: 10.1128/am.7.4.199-201.1959 -
Biochemical Pharmacology Jan 1977
Topics: Animals; Brain; In Vitro Techniques; Kinetics; Lactones; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Propiolactone; Propionates; Rats; Serotonin
PubMed: 831726
DOI: 10.1016/0006-2952(77)90131-9 -
Journal of Immunology (Baltimore, Md. :... May 1964
Topics: Animals; Antigens; Arboviruses; Complement Fixation Tests; Lactones; Mice; Propiolactone; Research
PubMed: 14170419
DOI: No ID Found -
Thrombosis Research May 1983The thrombogenicity of beta-PL/UV-treated PPSB (factor IX concentrate) was evaluated in chimpanzees. PPSB isolated from beta-propiolactone-treated and UV-irradiated...
The thrombogenicity of beta-PL/UV-treated PPSB (factor IX concentrate) was evaluated in chimpanzees. PPSB isolated from beta-propiolactone-treated and UV-irradiated plasma was injected into chimpanzees at a dose of approximately 100 units/kg body weight. An FDA licensed PPSB preparation served as the negative control, and a preparation containing activated as well as precursor clotting factors served as the positive control. 15 minutes, 1 h, 4 h, and 24 h after the PPSB application the following parameters were determined in the chimpanzee blood: factors II, VII, IX, X, VIII, fibrinogen, AT III, thrombin coagulase, Quick value, APTT and platelet count. Neither the untreated control preparation, nor the PPSB isolated from beta-propiolactone-treated and UV-irradiated plasma, showed signs of thrombogenicity in the chimpanzee model. The positive control indicated that the chimpanzee is a suitable model for the thrombogenicity testing of activated clotting factors.
Topics: Animals; Factor IX; Female; Lactones; Male; Pan troglodytes; Propiolactone; Thrombosis; Ultraviolet Rays
PubMed: 6868023
DOI: 10.1016/0049-3848(83)90077-4 -
Annals of the New York Academy of... Jan 1960
Topics: Humans; Lactones; Propiolactone; Virus Inactivation; Viruses
PubMed: 14417982
DOI: 10.1111/j.1749-6632.1960.tb40931.x -
Journal of Environmental Pathology and... 1979Scored at 24 hours, the LD-50 of a solution of beta-propiolactone administered intravenously to young rats was 225 +/- 55 mg/kg. Twenty-four hours after a single... (Comparative Study)
Comparative Study
Scored at 24 hours, the LD-50 of a solution of beta-propiolactone administered intravenously to young rats was 225 +/- 55 mg/kg. Twenty-four hours after a single intravenous injection (100 mg/kg = 1.4 m mole/kg) of beta-propiolactone into male and female rats of both the Long-Evans and Sprague-Dawley strains, the incidence of breaks found in the chromosomes of metaphase marrow cells was low (8.8 percent vs. 5.0 percent in controls). The s5 chromosomes were preferentially damaged. A 200 mg/kg dose increased the incidence modestly to 11.3 percent. In comparison, a single intravenous dose of benzo(a)pyrene (40 mg/kg = 0.16 m mole/kg) produced a break incidence of 19 percent. In long-term experiments multiple (five) intravenous injections (100 mg/kg each) of beta-propiolactone given in a 6 week period elicited only two neoplasms (a chloro-leukemia and a mammary fibroadenoma) among 37 animals during the following 12-13 months. In contrast, four injections of benzo(a)pyrene (40 mg/kg) produced a 14-times greater mammary tumor incidence in the Sprague-Dawley female rat than did beta-propiolactone. Marrow cell chromosome examination indicated no significant chromosomal changes due to the earlier beta-propiolactone treatment except for one animal with a consistent 43-chromosome karyotype resulting from S1 trisomy; no neoplasm was evident in that animal. Earlier treatment with benzo(a)pyrene produced a persistent and significant elevation in break incidence. Both the carcinogenic and clastogenic effects of intravenous beta-propiolactone are low in rats and are not comparable in magnitude to those produced by benzo(a)pyrene.
Topics: Animals; Benzopyrenes; Carcinogens; Chromosome Aberrations; Chromosomes; Colchicine; Female; Lactones; Lethal Dose 50; Male; Neoplasms, Experimental; Propiolactone; Rats
PubMed: 528852
DOI: No ID Found